Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
News|Articles|September 3, 2025
- Vol 53 No 09
- Volume 53
- Issue 09
Top 5 benign urology headlines you missed in August 2025
Fact checked by: Hannah Clarke
We recap notable headlines from last month in the benign urology space.
Advertisement
Advertisement
The month of August contained a plethora of noteworthy research and expert perspective across benign conditions in urology. This included an exclusive case report of a single-stage transvaginal repair of erosion of ring pessary with bladder rupture and complete eversion, a report on vaginal estrogen tablets and recurrent ischemic stroke, a recap of studies comparing surgical procedures for pediatric kidney stones, and more.
Related to this article
These FAQs outline key recommendations and practical takeaways from the 2026 AUA Medical Management of Kidney Stones guideline amendment.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Advertisement
Advertisement